Go to main page

hTME-3DX Screen and Verify™

The first drug screening platform to combine humanized 3D cell culture and patient-derived xenograft models

Download the hTME-3DX Screen and Verify Fact Sheet

hTME-3DX Screen and Verify™ Drug Screening Platform Fact Sheet
    You may unsubscribe from these communications at any time. Every email we send you will also include an unsubscribe link so you can unsubscribe from our marketing list. For more information on our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Advanced Models for Human Cancer

BioDuro’s hTME-3DX Screen and Verify™ is a 2-step preclinical tumor testing platform to identify the most efficacious oncology drug candidates and potential patient populations:

  • SCREEN with confidence: Ex vivo humanized 3D culture with 300 primary patient tumors
  • VERIFY for assurance: In vivo matched patient-derived xenograft models

 

Drug Screening Platform - Diverse and biologically relevant drug screening in hTME-3DX platform

Humanized tumor microenvironment, three-dimensional drug screening and patient-derived xenograft verification platform

BioDuro’s 300 hTME-3DX Screen and Verify™ models

  • Primary human tumor samples from the world’s largest bank of clinically annotated viable cryopreserved tumor cells
  • Molecular characterization of all tumor models
  • Established from US population, with matched histology/path review and associated ex vivo treatment data
  • Matching DNA, RNA and protein available for screening targets of interest
  • Profiled against a panel of 25+ SOC drugs, with clinically validated diagnostic testing for Extreme Drug Resistance (EDR) recorded as extreme, intermediate, or low

Additional benefits of hTME-3DX Screen and Verify™ models

  • Reduce animal testing in preclinical phases
  • Maintain throughput capability while using complex tumor models
  • Achieve greater cost and time efficiencies in drug screening
  • Rationalized workflow from 3D drug screening to PDX verification with the same set of patient tumors
  • Enable further characterization, in vivo, PK, PD experiments, and broader MoA studies to increase relevance of overall data package